Celltrion presents post hoc analysis of LIBERTY studies of ZYMFENTRA®  (infliximab-dyyb) at the American College of Gastroenterology 2024 Annual Scientific Meeting ...Middle East

Pivotal LIBERTY studies (LIBERTY-CD and LIBERTY-UC) previously demonstrated superior efficacy of subcutaneous (SC) infliximab over placebo for maintenance therapy in patients with Crohn's disease (CD) and ulcerative colitis (UC)[1], [2] ZYMFENTRA® is the first and only FDA-approved...

Hence then, the article about celltrion presents post hoc analysis of liberty studies of zymfentra infliximab dyyb at the american college of gastroenterology 2024 annual scientific meeting was published today ( Tuesday 29/10/2024 - 10:32 PM ) and is available on PR Newswire ( Middle East ) The editorial team at PressBee has edited and verified it, and it may have been modified, fully republished, or quoted. You can read and follow the updates of this news or article from its original source.

Read More Details
Finally We wish PressBee provided you with enough information of ( Celltrion presents post hoc analysis of LIBERTY studies of ZYMFENTRA®  (infliximab-dyyb) at the American College of Gastroenterology 2024 Annual Scientific Meeting )

Also on site :

• Blessing Muzarabani ditches PSL team, joins KKR for IPL 2026
• Heart attack patients at risk as defibrillator supplies targeted in NHS hack
• Iranians tell the world: The war must continue until the Ayatollah’s regime collapses